This Lunit research program aims to enhance studies led by SITC members by enabling the use of AI for TME profiling, including quantitative immune phenotyping (IP) via three (3) IP classification - inflamed, excluded, desert.
Lunit, a leading provider of AI-powered solutions for cancer testing, has developed Lunit SCOPE IO® to quantify histology from H&E WSIs, including assessment of Tumor-Infiltrating Lymphocytes (TILs), and immune phenotypes. Other features identified which can be used for biomarker formation include tertiary lymphoid structures, macrophages, fibroblasts, endothelial cells, and mitosis.
These biomarkers have shown correlation with immune checkpoint inhibitor response in multiple tumor types (Shen et al, JITC 2024, Park et al JCO 2022), and in many other clinical settings.
The program will accept applications from SITC members for analysis of H&E slides for research studies, to assess biomarkers in the tumor microenvironment. An overview is included, and publications utilizing Lunit SCOPE IO are here.
SITC does not endorse any specific AI technology for TME profiling and is partnering with Lunit to extend a unique offering to the SITC membership.